HERON THERAPEUTICS, INC. /DE/ Increase (Decrease) in Deferred Revenue
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Increase (Decrease) in Deferred Revenue of $1.66 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-07
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$2.80M.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $772.00K.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$447.00K.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $4.14M.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for fiscal 2017 was $1.66M, a 51.41% increase from fiscal 2016.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for fiscal 2016 was $1.10M.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for fiscal 2011 was -$272.00K.
- HERON THERAPEUTICS, INC. /DE/ increase (decrease) in deferred revenue for fiscal 2010 was -$88.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$2.02M derived: sum of 2 quarters · filed 2018-11-07 | -$2.47M derived: sum of 3 quarters · filed 2018-11-07 | $1.66M 10-K · filed 2018-02-27 |
| 2017-09-30 | $772.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $325.00K derived: sum of 2 quarters · filed 2018-11-07 | $4.46M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | -$447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $3.69M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $4.14M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $1.10M 10-K · filed 2018-02-27 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $0.00 derived: sum of 2 quarters · filed 2014-03-07 | -$256.00K derived: sum of 3 quarters · filed 2014-03-07 | -$272.00K 10-K · filed 2014-03-07 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | -$256.00K derived: sum of 2 quarters · filed 2012-11-05 | -$272.00K 10-Q · filed 2012-11-05 | -$284.00K derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$272.00K 10-Q · filed 2012-08-09 | -$284.00K derived: sum of 3 quarters · filed 2013-03-01 | -$308.00K derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$16.00K 10-Q · filed 2012-05-10 | -$28.00K derived: sum of 2 quarters · filed 2013-03-01 | -$52.00K derived: sum of 3 quarters · filed 2013-03-01 | |
| 2010-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$36.00K derived: sum of 2 quarters · filed 2013-03-01 | -$88.00K 10-K · filed 2013-03-01 | |
| 2010-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$76.00K 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$52.00K 10-Q · filed 2011-08-08 | |||
| 2009-12-31 | -$640.00K 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |